Prevalence of erythromycin resistance in lower airway bacterial isolates from patients with stable COPD Source: Eur Respir J 2005; 26: Suppl. 49, 251s Year: 2005
Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD Source: Eur Respir J 2012; 40: 1344-1353 Year: 2012
Antibiotic treatment and prevention of exacerbations of COPD Source: Eur Respir Monogr 2013; 60: 96-106 Year: 2013
The effect of tobramycin nebulised solution in COPD patients with Pseudomonas aeruginosa in sputum (preliminary report) Source: Eur Respir J 2004; 24: Suppl. 48, 409s Year: 2004
Antibacterial activity of telithromycin (TEL) and comparators against bacterial pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 641s Year: 2004
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004) Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017
Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasisSource: Eur Respir J 2001; 18: Suppl. 33, 541s Year: 2001
COPD is associated with high levels of bacterial antibiotic resistance Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002
Proteolytic activity of sputum and serum in patients with COPD exacerbation in dependence on smoking Source: Eur Respir J 2003; 22: Suppl. 45, 416s Year: 2003
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013
The relation of sputum color to bacterial load in exacerbations of COPD Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008
A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis Source: Eur Respir J, 51 (2) 1702166; 10.1183/13993003.02166-2017 Year: 2018
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results Source: Eur Respir J 2012; 40: 17-27 Year: 2012
Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002
Presence of fungus in sputum of patients treated with antibiotics or inhaled steroids Source: Annual Congress 2010 - Bronchiectasis and respiratory infections caused by Pseudomonas Year: 2010
Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD Source: Eur Respir J 2009; 34: 1066-1071 Year: 2009
Reduced moxifloxacin exposure in patients with tuberculosis and diabetes Source: Eur Respir J, 54 (3) 1900373; 10.1183/13993003.00373-2019 Year: 2019
Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001
Six months azithromycin treatment in COPD patients with high risk of further exacerbations Source: International Congress 2017 – Management of COPD Year: 2017